Novo Nordisk’s Semaglutite Alzheimer’s Failure Sends Stock to 4-Year Low
Novo Nordisk A/S (NYSE: NVO) announced that semaglutide failed to slow disease progression in two...
Zelgen’s ZG006 Wins BTD for Neuroendocrine Carcinoma as First DLL3 Trispecific
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that ZG006, the world’s first trispecific antibody...
Hengrui’s Ivarmacitinib NDA Accepted for Non‑Radiographic Axial Spondyloarthritis
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the China National Medical...
AstraZeneca’s Durvalumab Wins China Approval for Stage III NSCLC After Sequential Chemoradiotherapy
AstraZeneca (AZ, NASDAQ: AZN) announced that Imfinzi (durvalumab) received National Medical Products Administration (NMPA) approval...
Qihan-Biotech’s QT-019B Universal CAR-T Wins Implied NMPA Approval
Hangzhou Qihan Biotech Co., Ltd. announced that its New Drug Clinical Trial (IND) application for...
Junshi’s JS001sc Subcutaneous PD-1 Meets Phase 3 Endpoint in NSCLC
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that its Phase 3 trial JS001sc-002-III-NSCLC...
Rimag Partners with Qingyang Government on AI Medical Imaging Infrastructure
Jiangxi Rimag Group Co., Ltd. (HKG: 2522) announced a Strategic Framework Cooperation Agreement with the...
Biogen Dayra Partnership Targets Immunology with Macrocyclic Peptides
Biogen Inc. (NASDAQ: BIIB) and Dayra Therapeutics announced a research collaboration to discover and develop...
CStone’s Sugemalimab Wins EU Approval for Stage III NSCLC, Expanding European Indication
CStone Pharmaceuticals (HKG: 2616) announced that the European Commission (EC) has approved a new indication...
Salubris’ SAL0139 Wins NMPA Nod for Hyperlipidemia Clinical Trial
Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced that its independently developed innovative small molecule...
Zhongsheng’s Onradivir Granules Enroll First Phase 3 Pediatric Influenza Patient
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced the enrollment and dosing of the first...
HBM and AstraZeneca Deepen ADC/TCE Collaboration as AstraZeneca Exercises License Options
HBM Holdings Limited (HKG: 2142) announced the renewal and deepening of its global strategic collaboration...
Kelun-Biotech’s Sac-TMT Achieves First ADC-IO NSCLC Success
Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that sacituzumab tirumotecan (sac-TMT), its proprietary TROP2 ADC,...
Luye’s LY03017 Wins FDA Nod for Psychosis Trials in Alzheimer’s and Parkinson’s
Luye Pharma Group Limited (HKG: 2186) announced that its independently developed LY03017 received U.S. FDA...
CSPC’s SYH2056 Wins NMPA Nod for Depression Trials as Fast‑Acting 5‑HT2A Agonist
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2056, a selective 5‑HT2A receptor agonist, received...
Biokin’s iza-bren NDA Accepted for Nasopharyngeal Carcinoma, Advancing Bispecific ADC
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its New Drug Application (NDA) for...
Phrontline Raises $60M Series Pre‑A+ to Advance Bispecific ADC Pipeline
Phrontline Biopharma, a next‑generation antibody‑drug conjugate (ADC) company, announced the close of an oversubscribed USD...
Valo Health Partners with Merck on $3B Parkinson’s Disease Discovery Deal
Valo Health, Inc. announced a strategic collaboration with Merck KGaA (ETR: MRK) to advance therapeutic...
NMPA Issues Export Drug Certification Rules, Expanding Scope and Validity
China’s National Medical Products Administration (NMPA) released the “Regulations on Inspection and Export Certification Management...
Bayer’s HYRNUO Wins FDA Approval for HER2-Mutated Lung Cancer
Bayer AG (ETR: BAYN) announced that sevabertinib (trade name HYRNUO) received U.S. FDA approval for...